Use of Cuban recombinant human erythropoietin in Parkinson's disease treatment

MEDICC Review

Volumn 14, Issue 1, 2012, Pages 11-17

  Pedroso, Ivonne ^a   Bringas Vega, María Luisa ^a   Aguiar, Anubis ^a   Morales, Lilia ^a   Álvarez, Mario ^a   Valdés, Pedro A ^b   Álvarez, Lázaro ^a  

^a CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

^b CUBAN NEUROSCIENCE CENTER   (Cuba)

Author keywords

Clinical trial; Cuba; Erythropoietin; ior EPOCIM; Neuroprotective agents; Parkinson disease; Recombinant proteins; Safety

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; COGNITION; CUBA; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INJECTION SITE REACTION; KIDNEY COLIC; MALE; MOTOR PERFORMANCE; NEUROPROTECTION; PARKINSON DISEASE; SIDE EFFECT; TREATMENT DURATION;

AGED; BLOOD PRESSURE; CUBA; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84856462230     PISSN: 15557960     EISSN: 15273172     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Allain H, Bentué-Ferrer D, Akwa Y. Disease-modifying drugs and Parkinson's disease. Prog Neurobiol. 2008 Jan;84(1):25-39. (Pubitemid 350258711)
2. Giroud Benítez JL, Collado-Mesa F, Esteban EM. [Prevalence of Parkinson disease in an urban area of the Ciudad de La Habana province, Cuba. Door-to-door population study]. Neurologia. 2000 Aug-Sep;15(7):269-73. Spanish.
3. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011;26 Suppl 1:S1-58.
4. Barbosa MT, Caramelli P, Maia DP, Cunningham MC, Guerra HL, Lima-Costa MF, et al. Parkinsonism and Parkinson's disease in the elderly: A community-based survey in Brazil (the Bambuí study). Mov Disord. 2006 Jun;21(6):800-8. (Pubitemid 44028300)
5. NeuroInsights [Internet]. San Francisco (US): NeuroInsights; c2010. The Neurotechnology Industry 2010 Report; 2010 May 19 [cited 2011 Jun 27]. Available from: http://www.neuroinsights.com/marketreports/marketreport2010.html
6. Mena MA, Rodriguez-Navarro JA, Ros R, de Yebenes JG. On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease? Curr Med Chem. 2008;15(23):2305-20.
7. Rascol O. [Treatments in the early stage of Parkinson disease]. Rev Neurol (Paris). 2008 Apr;164 Spec No 2:F77-84. French.
8. Vale S. Current Management of the Cognitive Dysfunction in Parkinson's Disease: How Far Have We Come? Exp Biol Med (Maywood). 2008 Aug;233(8):941-51.
9. Esposito E, Cuzzocrea S. New Therapeutic Strategy for Parkinson's and Alzheimer's disease. Curr Med Chem. 2010;17(25):2764-74.
10. Frede S, Freitag P, Geuting L, Konietzny R, Fandrey J. Oxygen-regulated expression of the erythropoietin gene in the human renal cell line REPC. Blood. 2011 May 5;117(18):4905-14.
11. Kook YH, Ka M, Um M. Neuroprotective cytokines repress PUMA induction in the 1-methyl-4-phenylpyridinium (MPP(+)) model of Parkinson's disease. Biochem Biophys Res Commun. 2011 Jul 29;411(2):370-4.
12. Ostrowski D, Ehrenreich H, Heinrich R. Erythropoietin promotes survival and regeneration of insect neurons in vivo and in vitro. Neuroscience. 2011 Aug 11;188:95-108.
13. Badzek S, Curiæ Z, Krajina Z, Plestina S, Golubiæ- Cepuliæ B, Radman I. Treatment of Cancer-Related Anaemia. Coll Antropol. 2008 Jun;32(2):615-22.
14. Mainie P. Is there a role for erythropoietin in neonatal medicine? Early Hum Dev. 2008 Aug;84(8):525-32.
15. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002 Aug;8(8):495-505. (Pubitemid 36337492)
16. Boesch S, Sturm B, Hering S, Goldenberg H, Poewe W, Scheiber-Mojdehkar B. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol. 2007 Nov;62(5):521-4. (Pubitemid 350308777)
17. Boesch S, Sturm B, Hering S, Scheiber-Mojdehkar B, Steinkellner H, Goldenberg H, et al. Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: A clinical pilot trial. Mov Disord. 2008 Oct 15;23(13):1940-4.
18. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007 Oct;130(Pt 10):2577-88. (Pubitemid 47511714)
19. Ehrenreich H, Degner D, Meller J, Brines M, BéhéM, Hasselblatt M, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry. 2004 Jan;9(1):42-54. (Pubitemid 38175081)
20. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):573-94.
21. Pérez-Oliva JF, Casanova-González M, García- García I, Porrero-Martín PJ, Valenzuela-Silva CM, Hernández-Montero T, et al. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study. BMC Nephrol. 2005 May 23;6:5.
22. Vargas A, Mendoza I, Uranga R, González A, Martínez L, Caballero I, et al. Efficacy and Safety of ior®EPOCIM for Chemotherapy- or Radiotherapy-Induced Anemia in Pediatric Cancer Patients. MEDICC Rev. 2010 Jul;12(3):27-31.
23. Bayés B, Serra A, Juncà J, Lauzurica R. Successful treatment of anaemia of nephrotic syndrome with recombinant human erythropoietin. Nephrol Dial Transplant. 1998 Jul;13(7):1894-5. (Pubitemid 28306847)
24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4.
25. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427-42.
26. Pichot P, López-Ibor JJ, Valdés M. DSMIV Manual diagnóstico y estadístico de los trastornos mentales. Barcelona: Masson; 1995. Spanish.
27. Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7(1):2-13.
28. De Cos MA, Flórez J. Reacciones Adversas de los Medicamentos. In: Flórez J, editor. Farmacología humana. 3rd ed. Barcelona: Masson; 1998. p. 155-64. Spanish.
29. Tsitsimpikou C, Kouretas D, Tsarouhas K, Fitch K, Spandidos DA, Tsatsakis A. Applications and Biomonitoring Issues of Recombinant Erythropoietins for Doping Control. Ther Drug Monit. 2011 Feb;33(1):3-13.
30. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, et al. Practice Guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005 Apr;23(4):697-701. (Pubitemid 40523262)
31. Mattis S. Dementia Rating Scale. Odessa, Fl: Psychological Assessment Resources Inc; 1988.
32. Williams JB. A Structured Interview Guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988 Aug;45(8):742-7.
33. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. New York: Springer-Verlag; 2000 May 5. 528 p.
34. Signore AP, Weng Z, Hastings T, Van Laar AD, Liang Q, Lee YJ, et al. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J Neurochem. 2006 Jan;96(2):428-43.
35. Csete M, Rodriguez L, Wilcox M, Chadalavada S. Erythropoietin receptor is expressed on adult rat dopaminergic neurons and erythropoietin is neurotrophic in cultured dopaminergic neuroblasts. Neurosci Lett. 2004 Apr 8;359(1-2):124-6. (Pubitemid 38446653)
36. Obeso JA, Merello M, Rodríguez-Oroz MC, Marin C, Guridi J, Alvarez L. Levodopa-induced dyskinesias in Parkinson's disease. Handb Clin Neurol. 2007;84:185-218.
37. Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, Cowen PJ, et al. Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients. Psychopharmacology (Berl). 2010 Jun;210(3):419-28.
38. Sargin D, El-Kordi A, Agarwal A, Müller M, Wojcik SM, Hassouna I, et al. Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice. BMC Biol. 2011 Apr 28;9:27.
39. Sözmen SC, Kurul SH, Yis U, Tuǧyan K, Baykara B, Yilmaz O. Neuroprotective effects of recombinant human erythropoietin in the developing brain of rat after lithium-pilocarpine induced status epilepticus [Internet]. Brain Dev. 2011 May 18 [cited 2011 Jun 27]. Available from: http://www. sciencedirect.com/science/article/pii/S0387760411001367
40. Alvarez L, Macias R, Lopez G, Alvarez E, Pavon N, Rodriguez-Oroz MC, et al. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. Brain. 2005 Mar;128(Pt 3):570-83. (Pubitemid 40380192)
41. Diederich NJ, Goetz CG. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology. 2008 Aug 26;71(9):677-84.